Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press1510.36691/RJA15ArticlesСтатьиReview ArticleAn issue of selecting of immunobiological therapy of bronchial asthmaК вопросу выбора иммунобиологической терапии бронхиальной астмыIlinaN IИльинаНаталья Ивановна

главный врач, зам. директора по лечебной работе, доктор медицинских наук, профессор.

instimmun@yandex.ruNRC Institute of Immunology FMBA of RussiaФГБУ «ГНЦ Институт иммунологии» ФМБА России15022019161VOL 16, NO1 (2019)ТОМ 16, №1 (2019)91210032020Copyright ©; 2019, Pharmarus Print MediaCopyright ©; 2019, Фармарус Принт Медиа2019Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/15

The results of indirect treatment comparison of the efficacy of anti-Il-5 pathway therapies in severe eosinophilic asthma on the basis of network meta-analysis and Cochrane review are presented in the article.

В статье представлены результаты непрямого сравнения исследований эффективности анти-ИЛ-5-терапии при тяжелой эозинофильной астме на основании мета-анализа плацебо-контролируемых исследований и кохрановского обзора.

bronchial asthmatarget therapymonoclonal antibodiesIL-5mepolizumabreslizumabbenralizumabnetwork meta-analysisCochrane reviewбронхиальная астматаргетная терапиямоноклональные антителаИЛ-5меполизумабреслизумаббенрализумабмета-анализкохрановский обзорИнструкция по медицинскому применению лекарственного препарата Нукала. https://grls.rosminzdrav.ru/Grls_ View_v2.aspx?routingGuid=c9500b78-9cf6-45c9-8336-16ef-5348b722&t= Дата обращения: 26.10.2018Инструкция по медицинскому применению лекарственного препарата Синкейро. https://grls.rosminzdrav. ru/Grls_View_v2.aspx?routingGuid=d2f201db-73ab-465c-afb8-3a04f78e1608&t=. Дата обращения: 26.10.2018Ortega HG, Yancey SW, Mayer B., Gunsoy NB, Keene ON, Bleecker ER et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549-556.Ortega HG. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl J. Med. 2014;371:1198-1207.Pavord ID, Korn S., Howarth P., Bleecker eR, Buhl R., Keene N. et al. Mepolizumab for severe eosinophilic asthma (DREAM) : a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-659.Castro M., Zangrilli J., Wechsler ME, Bateman ED, Brusselle GG, Bardin P. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomized, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355-366.Bleecker ER, FitzGerald JM, Chanez P., Papi A., Weinstein SF, Barker P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting ß2-agonists (SIROCCO): a randomized, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115-2127.FitzGerald JM, Bleecker ER, Nair P., Korn S., Ohta K., Lommatzsch M. et al. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128-2141.Cabon Y., Molinari N., Marin G., Vachier I., Gamez AS, Chanez P. et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47:129-138.Farne HA, Wilson A., Powell C., Bax L., Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834.Castro M., Mathur S., Hargreave F., Boulet LP, Xie F., Young J. et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J. Respir Crit Care Med. 2011;184:1125-1132.Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J., Nelsen LM et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomized, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390-400.Bjermer L., Lemiere C., Maspero J., Weiss S., Zangrilli J., Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150:789-798.Corren J., Weinstein S., Janka L., Zangrilli J., Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799-810.FitzGerald JM, Bleecker ER, Menzies-Gow A., Zangrilli JG, Hirsch I., Metcalfe P. et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis ofthe SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6:51-64.Brusselle G., Germinaro M., Weiss S., Zangrilli J. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017;43:39-45.Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin Epidemiol. 1997;50:683-691.Методические рекомендации по проведению непрямых сравнений лекарственных препаратов. ФГБУ «ЦЭККМП» Минздрава России. М., 2017DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7;177-188.Rucker G., Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.